The Pharma Data

OCTOBER 25, 2020

Food and Drug Administration (“FDA”) for the treatment of agitation associated with delirium. Treatment choices are limited, and commonly used off-label therapies are not always effective or may result in prolonged, deep sedation. The Company plans to initiate a Phase 2 trial within the next several months. “We

Treatment 52

Treatment Trials FDA Hospitals 52

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.” Casirivimab and imdevimab injection is not FDA approved for any use.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

DECEMBER 29, 2020

The benefit was driven by results starting one week post-treatment, when the risk of death or receiving mechanical ventilation was reduced by approximately half with antibody cocktail treatment, based on a post-hoc analysis. Senior Vice President and Head of Global Clinical Development at Regeneron.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

APRIL 8, 2021

today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. P6: Neuromuscular Disorders and Clinical Trials. Spinal Muscular Atrophy (SMA).

Clinical Trials 52

Clinical Trials Trials Disease Nurses 52

The Pharma Data

AUGUST 11, 2020

development lead, Gastrointestinal Cancers, Bristol Myers Squibb. “We We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”. Waxman, M.D., While GEJ cancer has a lower prevalence than gastric cancer, it continues to rise.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the trial, treatment with Opdivo following neoadjuvant chemoradiation therapy (CRT) and complete surgical resection demonstrated a statistically significant improvement in the primary endpoint of DFS compared to placebo in the all-randomized population. MBA, Director of the Charles A.

Therapies 52

Therapies Trials Disease Treatment 52